APOBEC3D and APOBEC3F Potently Promote HIV-1 Diversification and Evolution in Humanized Mouse Model

PLoS Pathogens

Volumn 10, Issue 10, 2014, Pages

  Sato, Kei ^a   Takeuchi, Junko S ^a   Misawa, Naoko ^a   Izumi, Taisuke ^b,i   Kobayashi, Tomoko ^a,j   Kimura, Yuichi ^a   Iwami, Shingo ^c   Takaori Kondo, Akifumi ^d   Hu, Wei Shau ^b   Aihara, Kazuyuki ^e,f   Ito, Mamoru ^g   An, Dong Sung ^h   Pathak, Vinay K ^b   Koyanagi, Yoshio ^a  

^a KYOTO UNIVERSITY   (Japan)

^b NATIONAL CANCER INSTITUTE   (United States)

^c KYUSHU UNIVERSITY   (Japan)

^d KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e INSTITUTE OF INDUSTRIAL SCIENCE   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

^g CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS   (Japan)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF TOKUSHIMA   (Japan)

^j TOKYO UNIVERSITY OF AGRICULTURE   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MRNA EDITING ENZYME, CATALYTIC POLYPEPTIDE LIKE 3; APOLIPOPROTEIN B MRNA EDITING ENZYME, CATALYTIC POLYPEPTIDE LIKE 3D; APOLIPOPROTEIN B MRNA EDITING ENZYME, CATALYTIC POLYPEPTIDE LIKE 3F; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; MESSENGER RNA; PROTEIN; UNCLASSIFIED DRUG; VIF PROTEIN; VIRUS RNA; APOBEC3D PROTEIN, HUMAN; APOBEC3F PROTEIN, HUMAN; CYTIDINE DEAMINASE; CYTOSINE DEAMINASE;

ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BIOINFORMATICS; BLOOD SAMPLING; CELL ISOLATION; CONTROLLED STUDY; DATA ANALYSIS; EVOLUTION; FLOW CYTOMETRY; GENETIC TRANSFECTION; GENOME; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOASSAY; KINETICS; MONONUCLEAR CELL; MOUSE; MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; POLYMERASE CHAIN REACTION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN STRUCTURE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SEMIQUANTITATIVE 3D POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; VIRUS REPLICATION; WESTERN BLOTTING; ANIMAL; CHROMOSOME MAP; DISEASE MODEL; GENETIC VARIABILITY; GENETICS; METABOLISM; PHYSIOLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANIMALS; BIOLOGICAL EVOLUTION; CHROMOSOME MAPPING; CYTIDINE DEAMINASE; CYTOSINE DEAMINASE; DISEASE MODELS, ANIMAL; GENETIC VARIATION; HIV-1; HUMANS; MICE; MUTATION; RECEPTORS, CXCR4; RNA, VIRAL; VIRUS REPLICATION;

EID: 84908339006     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004453     Document Type: Article

References (81)

1. Conticello SG, (2008) The AID/APOBEC family of nucleic acid mutators. Genome Biol 9: 229.
2. Conticello SG, Langlois MA, Yang Z, Neuberger MS, (2007) DNA deamination in immunity: AID in the context of its APOBEC relatives. Adv Immunol 94: 37–73.
3. Teng B, Burant CF, Davidson NO, (1993) Molecular cloning of an apolipoprotein B messenger RNA editing protein. Science 260: 1816–1819.
4. Harris RS, Liddament MT, (2004) Retroviral restriction by APOBEC proteins. Nat Rev Immunol 4: 868–877.
5. Zhang J, (2003) Evolution by gene duplication: an update. Trends Ecol Evol 18: 292–298.
6. Sawyer SL, Emerman M, Malik HS, (2004) Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol 2: E275.
7. Stenglein MD, Burns MB, Li M, Lengyel J, Harris RS, (2010) APOBEC3 proteins mediate the clearance of foreign DNA from human cells. Nat Struct Mol Biol 17: 222–229.
8. Burns MB, Temiz NA, Harris RS, (2013) Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet 45: 977–983.
9. Shinohara M, Io K, Shindo K, Matsui M, Sakamoto T, et al. (2012) APOBEC3B can impair genomic stability by inducing base substitutions in genomic DNA in human cells. Sci Rep 2: 806.
10. Burns MB, Lackey L, Carpenter MA, Rathore A, Land AM, et al. (2013) APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 494: 366–370.
11. Sheehy AM, Gaddis NC, Choi JD, Malim MH, (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418: 646–650.
12. Izumi T, Shirakawa K, Takaori-Kondo A, (2008) Cytidine deaminases as a weapon against retroviruses and a new target for antiviral therapy. Mini Rev Med Chem 8: 231–238.
13. Dang Y, Wang X, Esselman WJ, Zheng YH, (2006) Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J Virol 80: 10522–10533.
14. Liddament MT, Brown WL, Schumacher AJ, Harris RS, (2004) APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr Biol 14: 1385–1391.
15. Refsland EW, Hultquist JF, Harris RS, (2012) Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n. PLoS Pathog 8: e1002800.
16. Miyagi E, Brown CR, Opi S, Khan M, Goila-Gaur R, et al. (2010) Stably expressed APOBEC3F has negligible antiviral activity. J Virol 84: 11067–11075.
17. Chaipan C, Smith JL, Hu WS, Pathak VK, (2013) APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages. J Virol 87: 444–453.
18. Pillai SK, Wong JK, Barbour JD, (2008) Turning up the volume on mutational pressure: is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3). Retrovirology 5: 26.
19. Casartelli N, Guivel-Benhassine F, Bouziat R, Brandler S, Schwartz O, et al. (2010) The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells. J Exp Med 207: 39–49.
20. Jern P, Russell RA, Pathak VK, Coffin JM, (2009) Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance. PLoS Pathog 5: e1000367.
21. Wood N, Bhattacharya T, Keele BF, Giorgi E, Liu M, et al. (2009) HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathog 5: e1000414.
22. Nie C, Sato K, Misawa N, Kitayama H, Fujino H, et al. (2009) Selective infection of CD4+ effector memory T lymphocytes leads to preferential depletion of memory T lymphocytes in R5 HIV-1-infected humanized NOD/SCID/IL-2Rγnull mice. Virology 394: 64–72.
23. Sato K, Izumi T, Misawa N, Kobayashi T, Yamashita Y, et al. (2010) Remarkable lethal G-to-A mutations in vif-proficient HIV-1 provirus by individual APOBEC3 proteins in humanized mice. J Virol 84: 9546–9556.
24. Sato K, Koyanagi Y, (2011) The mouse is out of the bag: insights and perspectives on HIV-1-infected humanized mouse models. Exp Biol Med 236: 977–985.
25. Sato K, Misawa N, Fukuhara M, Iwami S, An DS, et al. (2012) Vpu augments the initial burst phase of HIV-1 propagation and downregulates BST2 and CD4 in humanized mice. J Virol 86: 5000–5013.
26. Sato K, Misawa N, Nie C, Satou Y, Iwakiri D, et al. (2011) A novel animal model of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in humanized mice. Blood 117: 5663–5673.
27. Sato K, Nie C, Misawa N, Tanaka Y, Ito M, et al. (2010) Dynamics of memory and naive CD8+ T lymphocytes in humanized NOD/SCID/IL-2Rγnull mice infected with CCR5-tropic HIV-1. Vaccine 28 Suppl 2: B32–37.
28. Sato K, Misawa N, Iwami S, Satou Y, Matsuoka M, et al. (2013) HIV-1 Vpr accelerates viral replication during acute infection by exploitation of proliferating CD4+ T cells in vivo. PLoS Pathog 9: e1003812.
29. Fitzgibbon JE, Mazar S, Dubin DT, (1993) A new type of G→A hypermutation affecting human immunodeficiency virus. AIDS Res Hum Retroviruses 9: 833–838.
30. Gandhi SK, Siliciano JD, Bailey JR, Siliciano RF, Blankson JN, (2008) Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors. J Virol 82: 3125–3130.
31. Janini M, Rogers M, Birx DR, McCutchan FE, (2001) Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4+ T cells. J Virol 75: 7973–7986.
32. Pace C, Keller J, Nolan D, James I, Gaudieri S, et al. (2006) Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J Virol 80: 9259–9269.
33. Piantadosi A, Humes D, Chohan B, McClelland RS, Overbaugh J, (2009) Analysis of the percentage of human immunodeficiency virus type 1 sequences that are hypermutated and markers of disease progression in a longitudinal cohort, including one individual with a partially defective Vif. J Virol 83: 7805–7814.
34. Ulenga NK, Sarr AD, Hamel D, Sankale JL, Mboup S, et al. (2008) The level of APOBEC3G (hA3G)-related G-to-A mutations does not correlate with viral load in HIV type 1-infected individuals. AIDS Res Hum Retroviruses 24: 1285–1290.
35. Vartanian JP, Henry M, Wain-Hobson S, (2002) Sustained G→A hypermutation during reverse transcription of an entire human immunodeficiency virus type 1 strain Vau group O genome. J Gen Virol 83: 801–805.
36. Vartanian JP, Meyerhans A, Asjo B, Wain-Hobson S, (1991) Selection, recombination, and G→A hypermutation of human immunodeficiency virus type 1 genomes. J Virol 65: 1779–1788.
37. Kijak GH, Janini LM, Tovanabutra S, Sanders-Buell E, Arroyo MA, et al. (2008) Variable contexts and levels of hypermutation in HIV-1 proviral genomes recovered from primary peripheral blood mononuclear cells. Virology 376: 101–111.
38. Russell RA, Pathak VK, (2007) Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J Virol 81: 8201–8210.
39. Smith JL, Pathak VK, (2010) Identification of specific determinants of human APOBEC3F, APOBEC3C, and APOBEC3DE and African green monkey APOBEC3F that interact with HIV-1 Vif. J Virol 84: 12599–12608.
40. Suzuki Y, Koyanagi Y, Tanaka Y, Murakami T, Misawa N, et al. (1999) Determinant in human immunodeficiency virus type 1 for efficient replication under cytokine-induced CD4+ T-helper 1 (Th1)- and Th2-type conditions. J Virol 73: 316–324.
41. Krisko JF, Martinez-Torres F, Foster JL, Garcia JV, (2013) HIV restriction by APOBEC3 in humanized mice. PLoS Pathog 9: e1003242.
42. Koning FA, Newman EN, Kim EY, Kunstman KJ, Wolinsky SM, et al. (2009) Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J Virol 83: 9474–9485.
43. Refsland EW, Stenglein MD, Shindo K, Albin JS, Brown WL, et al. (2010) Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res 38: 4274–4284.
44. Lepelley A, Louis S, Sourisseau M, Law HK, Pothlichet J, et al. (2011) Innate sensing of HIV-infected cells. PLoS Pathog 7: e1001284.
45. von Sydow M, Sonnerborg A, Gaines H, Strannegard O, (1991) Interferon-α and tumor necrosis factor-α in serum of patients in various stages of HIV-1 infection. AIDS Res Hum Retroviruses 7: 375–380.
46. Pillai SK, Abdel-Mohsen M, Guatelli J, Skasko M, Monto A, et al. (2012) Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo. Proc Natl Acad Sci U S A 109: 3035–3040.
47. Stopak KS, Chiu YL, Kropp J, Grant RM, Greene WC, (2007) Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells. J Biol Chem 282: 3539–3546.
48. Hultquist JF, Lengyel JA, Refsland EW, LaRue RS, Lackey L, et al. (2011) Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J Virol 85: 11220–11234.
49. Suspene R, Rusniok C, Vartanian JP, Wain-Hobson S, (2006) Twin gradients in APOBEC3 edited HIV-1 DNA reflect the dynamics of lentiviral replication. Nucleic Acids Res 34: 4677–4684.
50. Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, et al. (2005) Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol 43: 406–413.
51. Yu Q, Konig R, Pillai S, Chiles K, Kearney M, et al. (2004) Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol 11: 435–442.
52. De Jong JJ, De Ronde A, Keulen W, Tersmette M, Goudsmit J, (1992) Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol 66: 6777–6780.
53. Shioda T, Levy JA, Cheng-Mayer C, (1992) Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 89: 9434–9438.
54. Lengauer T, Sander O, Sierra S, Thielen A, Kaiser R, (2007) Bioinformatics prediction of HIV coreceptor usage. Nat Biotechnol 25: 1407–1410.
55. Ebrahimi D, Anwar F, Davenport MP, (2012) APOBEC3G and APOBEC3F rarely co-mutate the same HIV genome. Retrovirology 9: 113.
56. Mulder LC, Ooms M, Majdak S, Smedresman J, Linscheid C, et al. (2010) Moderate influence of human APOBEC3F on HIV-1 replication in primary lymphocytes. J Virol 84: 9613–9617.
57. Bishop KN, Holmes RK, Malim MH, (2006) Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J Virol 80: 8450–8458.
58. Holmes RK, Koning FA, Bishop KN, Malim MH, (2007) APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J Biol Chem 282: 2587–2595.
59. Bishop KN, Verma M, Kim EY, Wolinsky SM, Malim MH, (2008) APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog 4: e1000231.
60. Gillick K, Pollpeter D, Phalora P, Kim EY, Wolinsky SM, et al. (2013) Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4+ T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination. J Virol 87: 1508–1517.
61. Kobayashi T, Koizumi Y, Takeuchi JS, Misawa N, Kimura Y, et al. (2014) Quantification of deaminase activity-dependent and -independent restriction of HIV-1 replication mediated by APOBEC3F and APOBEC3G through experimental-mathematical investigation. J Virol 88: 5881–5887.
62. Albin JS, Brown WL, Harris RS, (2014) Catalytic activity of APOBEC3F is required for efficient restriction of Vif-deficient human immunodeficiency virus. Virology 450–451: 49–54.
63. Mbisa JL, Bu W, Pathak VK, (2010) APOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different mechanisms. J Virol 84: 5250–5259.
64. Simon V, Zennou V, Murray D, Huang Y, Ho DD, et al. (2005) Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog 1: e6.
65. Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, et al. (2002) NOD/SCID/γcnull mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100: 3175–3182.
66. An DS, Poon B, Ho Tsong Fang R, Weijer K, Blom B, et al. (2007) Use of a novel chimeric mouse model with a functionally active human immune system to study human immunodeficiency virus type 1 infection. Clin Vaccine Immunol 14: 391–396.
67. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, et al. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46: 1896–1905.
68. Chiba-Mizutani T, Miura H, Matsuda M, Matsuda Z, Yokomaku Y, et al. (2007) Use of new T-cell-based cell lines expressing two luciferase reporters for accurately evaluating susceptibility to anti-human immunodeficiency virus type 1 drugs. J Clin Microbiol 45: 477–487.
69. Russell RA, Smith J, Barr R, Bhattacharyya D, Pathak VK, (2009) Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif. J Virol 83: 1992–2003.
70. Izumi T, Io K, Matsui M, Shirakawa K, Shinohara M, et al. (2010) HIV-1 viral infectivity factor interacts with TP53 to induce G2 cell cycle arrest and positively regulate viral replication. Proc Natl Acad Sci U S A 107: 20798–20803.
71. Sato K, Aoki J, Misawa N, Daikoku E, Sano K, et al. (2008) Modulation of human immunodeficiency virus type 1 infectivity through incorporation of tetraspanin proteins. J Virol 82: 1021–1033.
72. Sabbah A, Chang TH, Harnack R, Frohlich V, Tominaga K, et al. (2009) Activation of innate immune antiviral responses by Nod2. Nat Immunol 10: 1073–1080.
73. Thompson JD, Higgins DG, Gibson TJ, (1994) CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22: 4673–4680.
74. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, et al. (2011) MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 28: 2731–2739.
75. Darriba D, Taboada GL, Doallo R, Posada D, (2012) jModelTest 2: more models, new heuristics and parallel computing. Nat Methods 9: 772.
76. Tamura K, Nei M, (1993) Estimation of the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpanzees. Mol Biol Evol 10: 512–526.
77. Criscuolo A, (2011) morePhyML: improving the phylogenetic tree space exploration with PhyML 3. Mol Phylogenet Evol 61: 944–948.
78. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, et al. (2011) 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 19: 156–164.
79. Guo Y, Dong L, Qiu X, Wang Y, Zhang B, et al. (2014) Structural basis for hijacking CBF-β and CUL5 E3 ligase complex by HIV-1 Vif. Nature 505: 229–233.
80. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, et al. (1997) Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387: 188–191.
81. Markowitz M, Louie M, Hurley A, Sun E, Di Mascio M, et al. (2003) A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J Virol 77: 5037–5038.